FDA Accepts Biodel’s New Drug Application for Review

Biodel Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s new drug application seeking approval to market VIAject(R) for the treatment of diabetes. VIAject(R) is Biodel’s proprietary formulation of recombinant human insulin that is designed to be absorbed into the blood faster than currently marketed rapid-acting insulin analogs.
The new drug has been tested in more than 875 patients who participated in Phase 1, 2 and 3 clinical trials of the drug in the United States, Germany and India.

ASweetLife Team

Gary Taubes' Case for the Keto Diet: A Book Review “We believe than an injustice is being perpetrated that has to be righted.” Gary Taubes doesn’t mince words in his new book, The Case for Keto. The text is his…
Tandem’s X2 Insulin Pump Is First Device to Receive… Tandem Diabetes Care, Inc. announced that the U.S. FDA has classified the t:slim X2 insulin pump as the first in a new device category called Alternate Controller Enabled Infusion Pumps…
New Artificial Pancreas: FDA Authorizes Tandem… The U.S. FDA has authorized marketing of the Tandem Diabetes Care Control-IQ Technology, an interoperable automated glycemic controller device that automatically adjusts insulin delivery to a person with diabetes by…
FDA approves Lyumjev, Lilly’s New Rapid-Acting Insulin The U.S. FDA has approved Lyumjev, Lilly’s new rapid-acting insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes. Lyumjev (insulin lispro-aabc injection, 100 units/mL…
FDA: New Medtronic 770G Insulin Pump Approved for Ages 2+ The FDA has approved Medtronic's 770G insulin pump, the newest hybrid closed loop system, for use in patients as young as 2 years old. Parents of young children with Type…